乔优;袁媛;范俊平;孙雪峰;施举红;
QIAO You;YUAN Yuan;FAN Jun-ping;SUN Xue-feng;SHI Ju-hong;Department of Pulmonary and Critical Care Medicine,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College;

• 1:中国医学科学院北京协和医学院北京协和医院呼吸与危重症医学科

摘要(Abstract)：

目的探究急性肺栓塞溶栓治疗患者的短期预后相关因素。方法回顾性收集2014年1月至2017年11月北京协和医院经计算机断层扫描肺血管造影或超声心动图确诊并接受重组组织型纤溶酶原激活剂溶栓治疗的急性肺栓塞患者的临床资料,包括基础疾病、病程、临床特征、实验室检查、影像学表现、治疗及转归等,结合简化版肺栓塞严重指数,分析患者溶栓后7、14、30 d预后相关危险因素。结果共23例符合纳入和排除标准的患者入选本研究,其中男性5例,女性18例,平均年龄(57.3±14.0)岁。16例患者存活(69.6%,16/23),7例死亡(30.4%,7/23),7 d病死率为26.1%(6/23),14 d及30 d病死率均为30.4%(7/23)。与存活组相比,死亡组患者sPESI更高[3(2,3)比2(1,2),P=0.008],收缩压[(79.3±25.4)mm Hg比(108.7±18.1) mm Hg,P=0.005]、血小板计数[(135.1±58.3)×10~9/L比(223.2±89.4)×10~9/L,P=0.012]、血钙浓度[(1.9±0.2)mmol/L比(2.1±0.2)mmol/L,P=0.030]均更低,N端脑钠肽前体水平更高[6372(1637,17 228)pg/ml比1166(343,1821)pg/ml,P=0.035],心肺复苏更常见(100%比12.5%,P=0.000)。单因素生存分析显示,心率>110次/min(P=0.012)、收缩压<90 mm Hg(P=0.000)、进行心肺复苏(P=0.000)或N端脑钠钛前体水平>6000 pg/ml(P=0.001)的患者14 d生存率更低,而无恶性肿瘤、无慢性心肺疾病、动脉血氧饱和度≥90%、血小板≥200×10~9/L或血钙≥2.00 mmol/L并不能显著改善14 d存活情况。结论在急性肺栓塞溶栓患者中,低血压、心肺复苏、较高心率及N端脑钠肽前体水平可能预示着更高的短期死亡风险,低血钙、低血小板能否作为短期死亡预测因子仍需进一步研究论证。
Objective This study aimed to identify the possible short-term risk factors associated with the mortality of patients with acute pulmonary embolism after thrombolytic therapy. Methods We retrospectively collected the patients with acute pulmonary embolism who were diagnosed by computed tomography pulmonary angiography(CTPA) or echocardiography(ECHO) and received thrombolytic therapy with recombinant tissue-type plasminogen activator(rt-PA) in Peking Union Medical College Hospital from January 2014 to November 2017. The collection of clinical data including comorbidities, course of the disease, clinical features, laboratory tests, imaging findings, simplified pulmonary embolism severity index(sPESI), treatment, outcomes, etc. were used to analyze the prognostic factors of disease 7 days, 14 days and 30 days after thrombolytic therapy. Results A total of 23 patients, 5 males and 18 females, were included in the study with an average age of(57.3 ± 14.0) years. Sixteen patients survived(69.6%,16/23) and 7 died(30.4%,7/23); the 7-day, 14-day and 30-day mortality was 26.1%(6/23), and 30.4%(7/23), 30.4%(7/23), respectively. Compared to the survival group, patients in the death group had higher sPESI[3(2,3)vs 2(1,2),P=0.008], lower systolic pressure [(79.3±25.4)mm Hg vs(108.7±18.1)mm Hg, P=0.005], less platelets[(135.1±58.3)×10~9/L vs(223.2±89.4)×10~9/L, P=0.012], lower calcium concentration [(1.9±0.2)mmol/L vs(2.1±0.2)mmol/L, P=0.030], higher N-terminal pro-B-type natriuretic peptide(NT-proBNP) [6372(1637,17 228)pg/ml vs 1166(343,1821)pg/ml, P=0.035], and more frequent cardiopulmonary resuscitation(100% vs 12.5%, P=0.000). Survival analysis indicated that patients who had a heart rate>110 beats/min(P=0.012), systolic blood pressure <90 mm Hg(P=0.000), cardiopulmonary resuscitation(P=0.000), or NT-proBNP >6000 pg/ml(P=0.001) had a lower 14-day survival rate. Factors such as the absence of malignant tumors or chronic cardiopulmonary disease, arterial oxygen saturation ≥90%, platelets ≥200×10~9/L, and blood calcium ≥2.00 mmol/L made no difference in the improvement of 14-day survival. Conclusions In patients with acute pulmonary embolism after thrombolytic therapy, hypotension, cardiopulmonary resuscitation, elevated heart rate and NT-proBNP may indicate a higher risk of short-term mortality. Whether hypocalcemia and thrombocytopenia can be used as short-term prognostic factors requires further researches.

关键词(KeyWords)： 急性肺栓塞;溶栓治疗;重组组织型纤溶酶原激活剂;死亡风险;出血
acute pulmonary embolism;thrombolytic therapy;recombinant tissue-type plasminogen activator;mortality related risk;bleeding

Abstract:

Keywords:

基金项目(Foundation): 十三五精准医学研究“肺血栓栓塞症诊疗规范及应用方案的精准化研究”(2016YF0905603);; 北京市级大学生科研创新项目“中国人华法林相关基因多态性与个体化精准用药研究”(2017zlgc0650)

作者(Author): 乔优;袁媛;范俊平;孙雪峰;施举红;
QIAO You;YUAN Yuan;FAN Jun-ping;SUN Xue-feng;SHI Ju-hong;Department of Pulmonary and Critical Care Medicine,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College;

Email:

DOI:

参考文献(References)：

• [1] Tapson V.Acute pulmonary embolism[J].N Engl J Med,2008,358:1037- 1052.
• [2] Konstantinides SV.2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism[J].Eur Heart J,2014,35:3033- 3069.
• [3] Konstantinides SV,Mever G,Becattini C,et al.2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)[J].Eur Heart J,2020,41:543- 603.
• [4] Kucher N,Rossi E,Rosa MD,et al.Massive pulmonary embolism[J].Circulation,2006,113:577- 582.
• [5] Bradford MA,Lindenauer PK,Walkey AJ.Practice patterns and complication rates of thrombolysis for pulmonary embo-lism[J].J Thromb Thrombolysis,2016,42:313- 321.
• [6] Goldhaber SZ,Kessier CM,Heit J,et al.Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embo-lism[J].Lancet,1988,2:293- 298.
• [7] Meyer G,Sors H,Charbonnier B,et al.Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism:a European multi-center double-blind trial.The European Cooperative Study Group for Pulmonary Embolism[J].J Am Coll of Cardiol,1992,19:239- 245.
• [8] 王丹凤,江莲,唐良法.阿替普酶与尿激酶治疗急性肺栓塞溶栓的有效性及安全性研究[J].临床肺科杂志,2015,8:1465- 1468.
• [9] Ergan B,Ergün R,?alikan T,et al.Mortality Related Risk Factors in High-Risk Pulmonary Embolism in the ICU[J].Can Respir J,2016,2016:1- 8.
• [10] Goldhaber SZ.Echocardiography in the Management of Pulmonary Embolism[J].Ann Intern Med,2002,136:691- 700.
• [11] Kearon C,Akl EA,Ornelas J,et al.Antithrombotic Therapy for VTE Disease:CHEST Guideline and Expert Panel Report[J].Chest,2016,149:315- 352.
• [12] 颜虹.医学统计学[M].北京:人民卫生出版社,2010:113- 399.
• [13] Marshall PS,Mathews KS,Siegel MD.Diagnosis and management of life-threatening pulmonary embolism[J].J Intensive Care Med,2011,26:275- 294.
• [14] Henzler T,Roeger S,Meyer M,et al.Pulmonary embolism:CT signs and cardiac biomarkers for predicting right ventricular dysfunction[J].Eur Respir J,2012,39:919- 926.
• [15] Klok FA,Mos IC,Huisman MV.Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism:a systematic review and meta-analysis[J].Am J Respir Crit Care Med,2008,178:425- 430.
• [16] Lankeit M,Jimenez D,Kostrubiec M,et al.Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism[J].Eur Respir J,2014,43:1669- 1677.
• [17] Alonso-Martínez JL,Annicchérico-Sánchez FJ,Urbieta-Echezarreta MA,et al.N-terminal Pro-B type natriuretic peptide as long-term predictor of death after an acute pulmonary embolism[J].Med Clin (Barc),2015,144:241- 246.
• [18] Becattini C,Vedovati MC,Agnelli G.Prognostic value of troponins in acute pulmonary embolism:a meta-analysis[J].Circulation,2007,116:427- 433.
• [19] Aujesky D,Obrosky DS,Stone RA,et al.Derivation and validation of a prognostic model for pulmonary embolism[J].Am J Respir Crit Care Med,2005,172:1041- 1046.
• [20] Jiménez D,Aujesky D,Moores L,et al.Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism[J].Arch Intern Med,2010,170:1383- 1389.
• [21] Konstantinov IE,Saxena P,Koniuszko MD,et al.Acute massive pulmonary embolism with cardiopulmonary resuscitation:management and results[J].Tex Heart Inst J,2007,34:45- 46.
• [22] Dauphine C,Omari B.Pulmonary embolectomy for acute massive pulmonary embolism[J].Ann Surg,1982,195:726- 731.
• [23] Wood KE.Major pulmonary embolism:review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism[J].Chest,2002,121:877- 905.
• [24] 王建枝,钱睿哲.病理生理学[M].北京:人民卫生出版社,2015:265- 270.
• [25] Davlouros P,Xanthopoulou I,Mparampoutis N,et al.Role of Calcium in Platelet Activation:Novel Insights and Pharmacological Implications[J].Med Chem,2015,12:131- 138.
• [26] Owen WG,Bichler J,Ericson D,et al.Gating of thrombin in platelet aggregates by pO2-linked lowering of extracellular Ca2+ concentration[J].Biochemistry,1995,34:9277- 9281.
• [27] 彭斌,崔丽英.抗凝与出血:临床决策的平衡与选择[J].协和医学杂志,2018,9:97- 102.
• [28] Urokinase pulmonary embolism trial.Phase 1 results:a cooperative study[J].JAMA,1970,214:2163- 2172.
• [29] Daley MJ,Murthy MS,Peterson EJ.Bleeding risk with systemic thrombolytic therapy for pulmonary embolism:scope of the problem[J].Ther Adv Drug Saf,2015,6:57- 66.
• [30] Chatterjee S,Chakraborty A,Weinberg I,et al.Throm-bolysis for pulmonary embolism and risk of all-cause mortality,major bleeding,and intracranial hemorrhage:a meta-analysis[J].JAMA,2014,60:2414- 2421.
• [31] Meyer G,Gisselbrecht M,Diehl JL.Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism[J].Am J Med,1998,105:472- 477.
• [32] Curtis GM,Lam SW,Reddy AJ,et al.Risk factors associated with bleeding after alteplase administration for pulmonary embolism:a case-control study[J].Pharmacotherapy,2014,34:818- 825.